Parkman Healthcare Partners LLC Purchases 204,085 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Parkman Healthcare Partners LLC increased its stake in Ultragenyx Pharmaceutical Inc. by 203.8%, owning approximately $11.02 million worth of shares, making it the firm's 28th largest holding.
• Several institutional investors, including Alyeska Investment Group and Adage Capital Partners, also boosted their holdings in Ultragenyx, indicating strong investor interest.
• Ultragenyx's stock recently reported a 1.7% increase, with a market cap of $3.07 billion and analysts projecting a consensus rating of "Moderate Buy" with an average target price of $81.50.

Parkman Healthcare Partners LLC lifted its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 203.8% in the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 304,244 shares of the biopharmaceutical company's stock after buying an additional 204,085 shares during the period. Ultragenyx Pharmaceutical comprises about 1.3% of Parkman Healthcare Partners LLC's portfolio, making the stock its 28th biggest holding. Parkman Healthcare Partners LLC owned about 0.32% of Ultragenyx Pharmaceutical worth $11,017,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of RARE. Stifel Financial Corp raised its holdings in shares of Ultragenyx Pharmaceutical by 13.5% during the 4th quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock worth $1,001,000 after buying an additional 2,835 shares in the last quarter. Northern Trust Corp grew its position in Ultragenyx Pharmaceutical by 11.8% during the 4th quarter. Northern Trust Corp now owns 528,965 shares of the biopharmaceutical company's stock worth $22,254,000 after acquiring an additional 55,641 shares during the last quarter. Ameriprise Financial Inc. grew its position in Ultragenyx Pharmaceutical by 8.4% during the 4th quarter. Ameriprise Financial Inc. now owns 13,396 shares of the biopharmaceutical company's stock worth $564,000 after acquiring an additional 1,039 shares during the last quarter. BNP Paribas Financial Markets grew its position in Ultragenyx Pharmaceutical by 394.7% during the 4th quarter. BNP Paribas Financial Markets now owns 142,628 shares of the biopharmaceutical company's stock worth $6,000,000 after acquiring an additional 113,797 shares during the last quarter. Finally, BOKF NA grew its position in Ultragenyx Pharmaceutical by 5.0% during the 4th quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after acquiring an additional 382 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company's stock.

Wall Street Analysts Forecast Growth

RARE has been the topic of a number of research reports. Canaccord Genuity Group reduced their price objective on Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday. Guggenheim restated a "buy" rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Morgan Stanley reduced their price objective on Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating on the stock in a research report on Monday, July 14th. Finally, William Blair initiated coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an "outperform" rating and a $65.00 price objective on the stock. Eleven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $81.50.

Ultragenyx Pharmaceutical Stock Down 0.0%

RARE traded down $0.01 during midday trading on Tuesday, hitting $31.50. 936,948 shares of the company were exchanged, compared to its average volume of 1,277,080. The firm has a market capitalization of $3.04 billion, a P/E ratio of -5.70 and a beta of 0.21. Ultragenyx Pharmaceutical Inc. has a 1-year low of $25.81 and a 1-year high of $60.37. The firm's 50 day moving average price is $30.20 and its 200-day moving average price is $34.63.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. The company had revenue of $166.50 million for the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm's revenue was up 13.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.52) EPS. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total value of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is owned by corporate insiders.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.